AB050. SHR-1316 plus nab-paclitaxel and carboplatin as the first line therapy for advanced, unresectable, recurrent or metastatic thymic carcinoma
Abstract

AB050. SHR-1316 plus nab-paclitaxel and carboplatin as the first line therapy for advanced, unresectable, recurrent or metastatic thymic carcinoma

Ning Xu, Wentao Fang

Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence to: Wentao Fang, MD. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, West Huaihai Road No. 241, Shanghai 200030, China. Email: vwtfang@hotmail.com.

Background: For patients with advanced thymic carcinomas, National Comprehensive Cancer Network (NCCN) guidelines recommend chemotherapy (carboplatin/paclitaxel). But, with the limited efficacy of chemotherapy and high rate of disease progression, better treatments are in need. Thus, we started this single arm, phase II trial to evaluate the efficacy of combined treatment of chemotherapy and immunotherapy (ChiCTR2300072705).

Methods: Patients with unresectable, Union for International Cancer Control (UICC) stage III or IV, recurrent or metastatic thymic carcinomas without any previous anti-tumor therapy were enrolled. Patients were treated with SHR-1316 [targeting programmed death-ligand 1 (PD-L1)] (20 mg/kg) plus nab-paclitaxel (260 mg/m2) and carboplatin [area under the curve (AUC) 4–5] every 3 weeks for 4–6 cycles, then SHR-1316 monotherapy every 3 weeks for up to 2 years or till the disease progression. The primary end point was to evaluate the objective response rate (ORR).

Results: From July 2023 to July 2024, 14 patients were enrolled, 11 of which had evaluable response. The ORR was 54.5% (6/11), including 2 cases of complete response. Two patients had disease progression during SHR-1316 monotherapy. The most common grade 3–4 adverse events were leukocytopenia and neutropenia. Two patients had grade 3–4 immune related adverse events including asymptomatic increased lipase and myositis. No one died from the treatment or the disease till now.

Conclusions: Preliminary results showed that SHR-1316 plus nab-paclitaxel and carboplatin as the first-line therapy for advanced thymic carcinoma is effective and safe. As the trial carrying out, we look forward to more results.

Keywords: Thymic carcinoma; immunotherapy; chemotherapy

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://med.amegroups.com/article/view/10.21037/med-24-ab050/coif). W.F. serves as the Editor-in-Chief of Mediastinum from March 2017 to March 2027. The authors report receiving drug donation to enrolled patients from Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Shanghai, China). The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the ethics board of Shanghai Chest Hospital (No. IS23025) and informed consent was obtained from all individual participants.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/med-24-ab050
Cite this abstract as: Xu N, Fang W. AB050. SHR-1316 plus nab-paclitaxel and carboplatin as the first line therapy for advanced, unresectable, recurrent or metastatic thymic carcinoma. Mediastinum 2024;8:AB050.

Article Options

Download Citation

Share